KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 234 participants.

Also called NCT02268994

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 234 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02268994
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02268994. Randomized; quadruple masking; primary purpose treatment. Start 2014-10 (registry gives no type); primary completion 2016-01 (actual). Results posted on 2018-02-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
Condition
Anemia of Chronic Kidney Disease
Intervention (Drug)
ferric citrate
Intervention (Drug)
Placebo
Lead sponsor
Keryx Biopharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02268994
Content hash
e6ced8f970594d0b24f51325eacc34cc157f9d36059fb04ede98b3fb5cd12688